The NucliSENS easyMAG automated system was compared to the column-based Qiagen method for EpsteinBarr virus (EBV) or cytomegalovirus (CMV) DNA extraction from whole blood before viral load determination using the corresponding R-gene amplification kits. Both extraction techniques exhibited a total agreement of 81.3% for EBV and 87.2% for CMV.
method, i.e., QIAamp column DNA blood extraction kit according to the manufacturer's recommendations (Qiagen), or by the new specific B protocol on the NucliSENS easyMAG instrument. The latter protocol consists of the treatment of 200 l of whole blood in 2 ml of lysis buffer and the capture of nucleic acids by 140 l of magnetic silica. After incubation and washing procedures, nucleic acids were recovered in 50 l of elution buffer. EBV and CMV loads were quantified by using the respective R-gene amplification kit (Argene Biosoft) according to the manufacturer's recommendations. Both amplification kits have been previously validated for quantification of EBV and CMV load in whole blood (8, 11) . DNA extracts from both methods were amplified in the same run using an ABI 7500 instrument (Applied Biosystems).
Qualitative analysis. As shown in Table 1 , the overall agreement between the two extraction techniques was 81.3% (72.7 to 89.8%) for EBV and 87.2% (80.5 to 94.0%) for CMV. All the discrepant results corresponded to low DNA loads: between 20 and 459 copies/ml for the 15 samples not detected after Qiagen extraction for EBV and less than 1,000 copies/ml for the 12 samples found discordant for CMV results.
Quantitative analysis. The results of the samples found positive after extraction by both methods were retained for quantitative analysis (Fig. 1) . The correlation coefficients between the viral loads were 0.88 for EBV (P Ͻ 0.001) and 0.72 for CMV (P Ͻ 0.001). The mean between the difference in viral loads was 0.166 log 10 copies/ml to the benefit of the automated extraction method for EBV (P Ͻ 0.001) and Ϫ0.014 log 10 copies/ml for CMV (not statistically significant). All the results were included in the interval between the mean Ϯ 2 standard deviations, except for two and three samples for EBV and CMV, respectively. Both methods gave equivalent levels of quantification (difference of less than 0.5 log copies/ml) in 43 out of 52 samples (82.7%) for EBV and in 50 out of 60 samples (83.3%) for CMV. Seven of the nine samples with discrepancies of at least 0.5 log copies/ml for EBV load exhibited a higher quantification after easyMAG extraction, whereas the results of the 10 samples with discrepancies of at least 0.5 log copies/ml for CMV load were equally distributed in both directions.
QCMD panel analysis. Eight samples of the 2006 Quality Control for Molecular Diagnostics (QCMD, Scotland, United
Kingdom) CMV Proficiency Program were also tested. The results depicted in Fig. 2 show that the range of quantification was proportional by both techniques but that, for the four specimens tested in duplicate, the viral load was consistently higher by the automated method. The theoretical load of each sample (illustrated by the horizontal bars in Fig. 2 ) was close to the results of the Qiagen extraction, which is not surprising, since this technique or a related one was probably used for the extraction step of the experiment performed to define the reference values. Despite the small number of specimens and the limitation that the medium in which the different concentrations of CMV DNA were diluted was not whole blood, these results suggest a better ability of the automated extraction method to recover viral DNA. Detection of PCR inhibitors and gain in operational steps. Among all of the whole-blood specimens analyzed (n ϭ 174), an invalid result was found for two samples after DNA extraction by the NucliSENS easyMAG method and in two other samples by the Qiagen method; reextraction was successful for all of these samples. Evaluation of user convenience of both extraction methods showed that the turnaround time necessary to treat 24 samples was approximately 60 min by using the off-board protocol for the NucliSENS easyMAG instrument, including 30 min of hands-on time, whereas the extraction of 24 samples by the Qiagen technique was completed in 90 min of technician time starting from the addition of the lysis buffer.
Different automated extraction methods have been previously evaluated for EBV or CMV DNA extraction from whole blood (1, 3, 7, 9, 10, (13) (14) (15) (16) . To our knowledge, the present study is the first one that evaluated the performance of the NucliSENS easyMAG platform for determination of CMV and EBV loads from whole blood. Of note, the specific A protocol recommended by the manufacturer of the automated method for other clinical samples is not accurate for DNA-rich specimens such as whole blood (data not shown); the volume of silica particles and that of the lysis buffer were increased (specific B protocol) in order to recover the large amount of nucleic acids present in whole-blood specimens. This new protocol was shown to be at least as efficient as the manual Qiagen method to extract EBV and CMV DNA from whole-blood samples (Table 1 and Fig. 1) , with a slightly better sensitivity of the automated extraction technique for EBV DNA, as has been previously reported for different clinical samples (6) . The results of analysis of the specimens from the CMV QCMD panel also suggests a higher extraction rate obtained by the automated technique (Fig. 2) .
In addition to a higher sensitivity, notably with regard to low values, the advantages of this automated extraction technique include (i) a significant reduction of technical time, (ii) an absence of the risk of cross-contamination due to centrifugation steps, and (iii) an improvement in standardization, traceability, and quality control assessment.
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